194 related articles for article (PubMed ID: 25660173)
1. Diminished immune response to vaccinations in obesity: role of myeloid-derived suppressor and other myeloid cells.
Chen S; Akbar SM; Miyake T; Abe M; Al-Mahtab M; Furukawa S; Bunzo M; Hiasa Y; Onji M
Obes Res Clin Pract; 2015; 9(1):35-44. PubMed ID: 25660173
[TBL] [Abstract][Full Text] [Related]
2. Immunosuppressive functions of hepatic myeloid-derived suppressor cells of normal mice and in a murine model of chronic hepatitis B virus.
Chen S; Akbar SM; Abe M; Hiasa Y; Onji M
Clin Exp Immunol; 2011 Oct; 166(1):134-42. PubMed ID: 21762128
[TBL] [Abstract][Full Text] [Related]
3. Hepatitis B Virus Surface Antigen Activates Myeloid Dendritic Cells via a Soluble CD14-Dependent Mechanism.
van Montfoort N; van der Aa E; van den Bosch A; Brouwers H; Vanwolleghem T; Janssen HLA; Javanbakht H; Buschow SI; Woltman AM
J Virol; 2016 Jul; 90(14):6187-6199. PubMed ID: 27099316
[TBL] [Abstract][Full Text] [Related]
4. Humoral and cellular immune responses to hepatitis B vaccination in hepatitis B surface antigen-carrier children who cleared serum-hepatitis B surface antigen.
Hsu HY; Chang MH; Hsieh RP; Ni YH; Chi WK
Hepatology; 1996 Dec; 24(6):1355-60. PubMed ID: 8938161
[TBL] [Abstract][Full Text] [Related]
5. Strong and multi-antigen specific immunity by hepatitis B core antigen (HBcAg)-based vaccines in a murine model of chronic hepatitis B: HBcAg is a candidate for a therapeutic vaccine against hepatitis B virus.
Akbar SM; Chen S; Al-Mahtab M; Abe M; Hiasa Y; Onji M
Antiviral Res; 2012 Oct; 96(1):59-64. PubMed ID: 22884884
[TBL] [Abstract][Full Text] [Related]
6. γδT cells drive myeloid-derived suppressor cell-mediated CD8+ T cell exhaustion in hepatitis B virus-induced immunotolerance.
Kong X; Sun R; Chen Y; Wei H; Tian Z
J Immunol; 2014 Aug; 193(4):1645-53. PubMed ID: 25015833
[TBL] [Abstract][Full Text] [Related]
7. Synergistic and additive effects of cimetidine and levamisole on cellular immune responses to hepatitis B virus DNA vaccine in mice.
Niu X; Yang Y; Wang J
Scand J Immunol; 2013 Feb; 77(2):84-91. PubMed ID: 23298196
[TBL] [Abstract][Full Text] [Related]
8. Inducing oral immune regulation of hepatitis B virus envelope proteins suppresses the growth of hepatocellular carcinoma in mice.
Gotsman I; Alper R; Klein A; Rabbani E; Engelhardt D; Ilan Y
Cancer; 2002 Jan; 94(2):406-14. PubMed ID: 11900226
[TBL] [Abstract][Full Text] [Related]
9. IL-12-based vaccination therapy reverses liver-induced systemic tolerance in a mouse model of hepatitis B virus carrier.
Zeng Z; Kong X; Li F; Wei H; Sun R; Tian Z
J Immunol; 2013 Oct; 191(8):4184-93. PubMed ID: 24048897
[TBL] [Abstract][Full Text] [Related]
10. Posintro™-HBsAg, a modified ISCOM including HBsAg, induces strong cellular and humoral responses.
Schiött A; Larsson K; Manniche S; Kalliomäki S; Heydenreich AV; Dalsgaard K; Kirkby N
Int J Pharm; 2011 Jul; 414(1-2):312-20. PubMed ID: 21601626
[TBL] [Abstract][Full Text] [Related]
11. Tumor-induced myeloid-derived suppressor cell subsets exert either inhibitory or stimulatory effects on distinct CD8+ T-cell activation events.
Schouppe E; Mommer C; Movahedi K; Laoui D; Morias Y; Gysemans C; Luyckx A; De Baetselier P; Van Ginderachter JA
Eur J Immunol; 2013 Nov; 43(11):2930-42. PubMed ID: 23878002
[TBL] [Abstract][Full Text] [Related]
12. Vaccination with a fusion DNA vaccine encoding hepatitis B surface antigen fused to the extracellular domain of CTLA4 enhances HBV-specific immune responses in mice: implication of its potential use as a therapeutic vaccine.
Zhou C; Peng G; Jin X; Tang J; Chen Z
Clin Immunol; 2010 Nov; 137(2):190-8. PubMed ID: 20692873
[TBL] [Abstract][Full Text] [Related]
13. A novel therapeutic hepatitis B vaccine induces cellular and humoral immune responses and breaks tolerance in hepatitis B virus (HBV) transgenic mice.
Buchmann P; Dembek C; Kuklick L; Jäger C; Tedjokusumo R; von Freyend MJ; Drebber U; Janowicz Z; Melber K; Protzer U
Vaccine; 2013 Feb; 31(8):1197-203. PubMed ID: 23306359
[TBL] [Abstract][Full Text] [Related]
14. Polarization of Monocytic Myeloid-Derived Suppressor Cells by Hepatitis B Surface Antigen Is Mediated via ERK/IL-6/STAT3 Signaling Feedback and Restrains the Activation of T Cells in Chronic Hepatitis B Virus Infection.
Fang Z; Li J; Yu X; Zhang D; Ren G; Shi B; Wang C; Kosinska AD; Wang S; Zhou X; Kozlowski M; Hu Y; Yuan Z
J Immunol; 2015 Nov; 195(10):4873-83. PubMed ID: 26416274
[TBL] [Abstract][Full Text] [Related]
15. Induction of a robust T- and B-cell immune response in non- and low-responders to conventional vaccination against hepatitis B by using a third generation PreS/S vaccine.
Krawczyk A; Ludwig C; Jochum C; Fiedler M; Heinemann FM; Shouval D; Roggendorf M; Roggendorf H; Lindemann M
Vaccine; 2014 Sep; 32(39):5077-82. PubMed ID: 24975813
[TBL] [Abstract][Full Text] [Related]
16. Partial delipidation improves the T-cell antigenicity of hepatitis B virus surface antigen.
Desombere I; Willems A; Gijbels Y; Leroux-Roels G
J Virol; 2006 Apr; 80(7):3506-14. PubMed ID: 16537618
[TBL] [Abstract][Full Text] [Related]
17. CpG oligodeoxynucleotides with hepatitis B surface antigen (HBsAg) for vaccination in HBsAg-transgenic mice.
Malanchère-Brès E; Payette PJ; Mancini M; Tiollais P; Davis HL; Michel ML
J Virol; 2001 Jul; 75(14):6482-91. PubMed ID: 11413315
[TBL] [Abstract][Full Text] [Related]
18. Cytokine-dependent anti-viral role of CD4-positive T cells in therapeutic vaccination against chronic hepatitis B viral infection.
Ren F; Hino K; Yamaguchi Y; Funatsuki K; Hayashi A; Ishiko H; Furutani M; Yamasaki T; Korenaga K; Yamashita S; Konishi T; Okita K
J Med Virol; 2003 Nov; 71(3):376-84. PubMed ID: 12966542
[TBL] [Abstract][Full Text] [Related]
19. Cyclophosphamide-induced myeloid-derived suppressor cell population is immunosuppressive but not identical to myeloid-derived suppressor cells induced by growing TC-1 tumors.
Mikyšková R; Indrová M; Polláková V; Bieblová J; Símová J; Reiniš M
J Immunother; 2012 Jun; 35(5):374-84. PubMed ID: 22576342
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein gp96 enhances humoral and T cell responses, decreases Treg frequency and potentiates the anti-HBV activity in BALB/c and transgenic mice.
Wang S; Qiu L; Liu G; Li Y; Zhang X; Jin W; Gao GF; Kong X; Meng S
Vaccine; 2011 Aug; 29(37):6342-51. PubMed ID: 21600951
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
